A viral contamination at Genzyme’s Allston manufacturing plant forced the company to halt through July the production of drugs used to treat rare genetic disorders. About 8,000 patients are being affected.
(Janet Knott/Globe Staff/File 2007)
Finding the source
Genzyme says plant probably tainted by outside vendor, raising questions about other biotechs
A viral contamination at Genzyme’s Allston manufacturing plant forced the company to halt through July the production of drugs used to treat rare genetic disorders. About 8,000 patients are being affected.
(Janet Knott/Globe Staff/File 2007)
Genzyme Corp. said yesterday it still believes the virus that shut down its biotechnology drug manufacturing plant in Allston came from tainted nutrients received from an outside vendor, raising the possibility that the virus could infect other companies that use the same supplier. (Full article: 839 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
